**Name of Journal: *World Journal of Gastroenterology***

**ESPS Manuscript NO: 30114**

**Manuscript Type: ORIGINAL ARTICLE**

***Observational Study***

**disease impact on the quality of life of children with inflammatory bowel disease**

Chouliaras G *et al*. Quality of life in pediatric IBD

**Giorgos Chouliaras, Daphne Margoni, Konstantina Dimakou, Smaragdi Fessatou, Ioanna Panayiotou, Eleftheria Roma-Giannikou**

**Giorgos Chouliaras, Daphne Margoni, Konstantina Dimakou, Smaragdi Fessatou, Ioanna Panayiotou, Elefheria Roma-Giannikou,** First Department of Pediatrics, National and Kapodistrian University of Athens, “Aghia Sophia” Children’s Hospital, 11527 Athens, Greece

**Author contributions**: Chouliaras G and Margoni D contributed equally to this work; Roma E conceptualized and designed the study, supervised the analyses and wrote the manuscript. Chouliaras G is a medical biostatistician and performed the main statistical analysis; Chouliaras G and Margoni D designed the study, analysed the data and wrote the manuscript; Dimakou K, Fessatou S and Panayotou J participated in study design, data collection and manuscript preparation; all authors approved the final manuscript.

**Institutional review board statement**: The study was reviewed and approved by the Ethics Committee of “Aghia Sophia” Children’s Hospital, Athens, Greece

**Informed consent statement**: All study participants, or their legal guardian, provided informed consent prior to study enrolment.

**Conflict-of-interest statement**: There are no conflicts of interest to report.

**Data sharing statement**: No other data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to**: **Giorgos Chouliaras, MD, PhD,** First Department of Pediatrics, National and Kapodistrian University of Athens, “Aghia Sophia” Children’s Hospital, Thivon and Papadiamantopoulou street, 11527 Athens, Greece. georgehouliaras@msn.com

**Telephone:** +30-210-7467129

**Fax:** +30-21-32013237

**Received:** September 12, 2016

**Peer-review started:** September 12, 2016

**First decision:** October 20, 2016

**Revised:** November 16, 2016

**Accepted:** January 11, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To assess the impact of disease characteristics on the quality of life (QOL) in children with inflammatory bowel diseases (IBD).

***METHODS***

This was a cross-sectional study conducted at the First Department of Pediatrics of the University of Athens at the “Aghia Sophia” Children’s Hospital. Children diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC), who were followed as outpatients or during a hospitalization, participated, after informed consent was obtained from their legal representative. QOL was assessed by the IMPACT-III questionnaire. Demographic data and disease characteristics were also collected. Statistical analyses included parametric (Student’s *t*-test and Pearson’s r) and non-parametric (Mann-Whitney test, Fisher’s test and Spearman’s rho) procedures.

***RESULTS***

Ninety-nine patients (UC: 37, 73.0% females, CD: 62, 51.6% females), aged 12.8 ± 2.6 years were included. Overall, as well as, sub-domain scores did not differ between UC and CD (overall score: 73.9 ± 13.3 *vs* 77.5 ± 11.2, respectively, *p* = 0.16). In the entire sample, total score was related to physician’s global assessment (PGA, patients classified as “mild/moderate” active disease had, on average, 14.8 ± 2.7 points lower total scores compared to those “in remission”, *p* < 0.001) and age at IMPACT completion (Pearson’s *r* = 0.29, *p* = 0.05). Disease activity assessed by the indices PUCAI, PCDAI or PGA was significantly associated with all subdomains scores. Presence of extraintestinal manifestations had a negative impact on emotional and social functioning domains.

***CONCLUSION***

Disease activity is the main correlate of QOL in children with IBD, underlining the importance of achieving and sustaining clinical remission

**Key words:** Inflammatory bowel disease; ulcerative colitis; Crohn’s disease; quality of life; IMPACT-III; children

© **The Author(s) 2017**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study demonstrated that disease activity is the main correlate of quality of life (QOL) in children with inflammatory bowel diseases (IBD). Furthermore, several factors, that pose increased risks for impaired QOL for children with IBD, were identified. In brief, children of younger age, the early years after the diagnosis and the presence of extra-intestinal manifestations were inversely related to IMPACT-III scores. Therefore, in children with these specific features, physicians should be more vigilant in order to recognize and address issues related to their QOL promptly.

Chouliaras G, Margoni D, Dimakou K, Fessatou S, Panayiotou I, Roma-Giannikou E. disease impact on the quality of life of children with inflammatory bowel disease. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

Inflammatory bowel diseases (IBD) are immune mediated disorders with a genetic component, characterized by chronic inflammation of the gastrointestinal tract. Although patients suffering from these conditions have a normal life expectancy, the need for long-term medication, frequent hospitalizations, surgeries and the relapsing nature of the disease significantly negatively affect their quality of life (QOL). The term QOL encompasses the patients’ subjective perception of their health state, as well as the impact of their disease on their physical, social and emotional wellbeing[1].

There are several studies published on the subject, the majority of which support that patients with IBD, as with other chronic diseases, have an impaired QOL compared to the normal population[[1-3](#_ENREF_1)]. Most researchers have concluded that in patients with IBD the disease activity is the main predictive factor of QOL; however it is not yet defined how other disease characteristics, such as disease duration, recurrent hospitalizations or different treatment modalities affect their QOL.

In this study we assessed the QOL in Greek pediatric patients with IBD and attempted to identify how it is affected by disease characteristics.

**Materials and methods**

The study was conducted at the First Department of Pediatrics of the University of Athens, Greece after approval by the Ethics Committee of the “Aghia Sophia” Children’s Hospital in Athens, Greece. Informed consent was obtained from all legal representatives of the children who participated.

This was a cross-sectional study. Candidates for inclusion were children diagnosed with UC or CD according to the revised Porto criteria[[4](#_ENREF_4)], who were hospitalized or followed in the outpatient IBD clinic. All patients had undergone at least one full ileocolonoscopy with biopsies, esophago-gastro-duodenoscopy with biopsies and magnetic resonance enterography for small bowel assessment.

At the time of evaluation, a number of parameters were recorded: Demographic data, disease activity, disease duration, current treatment and number of hospitalizations in the previous 3 months. For the disease activity evaluation the Pediatric Crohn’s disease activity index (PCDAI)[[5](#_ENREF_5)] or the Pediatric Ulcerative Colitis activity index (PUCAI)[[6](#_ENREF_6)] were used. For PCDAI the score ranges from 0 to 100, whereas for PUCAI the score ranges from 0 to 85 points. Based on the activity indices patients were classified as being in remission (PCDAI ≤ 10 or PUCAI ≤ 10), in relapse with mild activity (10 < PCDAI ≤ 30 or 10 < PUCAI ≤ 34) and in relapse with moderate/severe activity (PCDAI > 30 or PUCAI > 34). Physician’s global assessment (PGA) was also recorded at the time of evaluation. PGA is a validated instrument through which the physician is able to evaluate disease activity clinically, on a 4 point scale (inactive, mild, moderate and severe disease).

QOL was assessed by the IMPACT-III questionnaire, which is a 35-item self-report tool that assesses QOL in children and adolescents with IBD. Children indicate on a 5-point Likert scale the extent to which they are bothered by specific aspects of their health condition. It consists of 6 subscales: bowel symptoms, systemic symptoms, emotional functioning, social functioning, body image and treatment/interventions. Scores range from 35 to 175, with higher scores suggesting better QOL. We used the Greek version of the questionnaire, created by one of the authors (Roma-Giannikou E), which has been translated from the original one designed by Otley and the Pediatric Inflammatory Bowel Disease Working Group on Quality of Life in 2002[[7](#_ENREF_7)]. The patients completed the IMPACT-III questionnaires, in the presence of their parent(s), in approximately 20 minutes.

***Statistical analysis***

Statistical analysis was performed by a medical biostatistician (GC). Summary statistics for continuous variables are presented as mean± standard deviation (SD) and compared by *t*-test, whereas in cases of small samples (< 30) or skewed distributions, median and interquartile range are presented and the Mann-Whitney test was used. Categorical data are presented as absolute (n) and relative (%) frequencies and compared by Fisher’s exact test. Correlations were assessed by Pearson’s correlation coefficient (*r*), or Spearman’s rho. Due to the small number of observations in the PGA-category «moderate», categories «mild» and «moderate» were collapsed into one class and compared to patients in «clinical remission». Similarly, as the numbers of subjects in the moderate/severe categories, according to PCDAI/PUCAI classification, were very small, patients were grouped as “in remission” or “in relapse with mild/moderate activity” and a new joined variable was formed including all individuals. After univariate analyses were performed, a stepwise backward regression analysis was performed to assess significant parameters at the multivariate level, grouping all IBD patients. Level of statistical significance, for univariate analyses, was set to 0.05. For the stepwise approach, the level for entering a covariate into the model was 0.051 whereas for removing, it was 0.05. All analyses were performed with Stata 11.0 MP statistical software (Stata Corp, TX, United States).

**RESULTS**

***Descriptive statistics***

A total of 99 patients (62 CD, 37 UC) were included in the analysis. Demographic data and disease characteristics are shown in table 1. Patients with CD were older at the time of diagnosis, as well as at the time of IMPACT completion and were more likely to be treated with an anti-TNFa agent. Table 2 illustrates total and sub-domain IMPACT scores, overall as well as according to diagnosis. In general, patients with CD scored higher in all scales compared to ulcerative colitis group; however the results did not reach statistical significance, not even after adjusting for PGA level (all *p*-values > 0.05). The only exception was emotional functioning domain, where among patients in clinical remission, according to PGA, CD children scored significantly higher compared to UC children (79.3 ± 16.2 *vs* 70.0 ± 21.1, *p* = 0.05).

***Total score of correlates of IMPACT scores***

In the entire study sample of IBD patients, the total IMPACT score was positively related to disease duration (Pearson’s *r* = 0.20, *p* = 0.04), age at IMPACT completion (Pearson’s *r* = 0.19, p=0.05) and inversely related to disease activity assessed by PUCAI and PCDAI (“in remission” vs “mild/moderate”: 79.6 ± 11.4 *vs* 68.0 ± 10.0, respectively, *p* < 0.001). Sub-analyses confirmed the relation between total IMPACT score and disease activity in both IBD groups (UC: Pearson’s *r* = -0.45, *p* = 0.005, CD: Pearson’s *r* = -0.42, *p* < 0.001) and between total IMPACT score and age at IMPACT completion only in the UC group (Pearson’s *r* = 0.29, *p* = 0.05). Disease duration was not a significant predictor in either group, in stratified analyses. Overall, total scores showed a significant trend across the PGA scale, with lower scores corresponding to worst clinical assessment (Mann-Whitney test, *p* < 0.001, figure 1a). The same result occurred in the stratified analyses (Mann-Whitney test, UC: *p* = 0.014 and CD: *p* < 0.001, figure 1b and c respectively).

Gender, number of hospitalizations in the previous 3 mo and type of medication were not correlated to total IMPACT scores neither overall or per group (all *p*-values > 0.10).

Finally a multivariate stepwise regression analysis was performed in the entire study sample. In the final model, PGA and age at IMPACT-III completion remained significant. More specifically, patients classified as “mild/moderate” had, on average, 14.5 ± 2.7 points lower total scores compared to those “in remission” (*p* < 0.001). In addition, it was estimated that one year increase in age at IMPACT-III completion increases the total score by an average of 0.8±0.4 points, regardless of PGA classification (*p* = 0.044).

***Sub-domain scores of correlates of IMPACT scores***

**Bowel symptoms:** Overall, the bowel symptoms domain score was significantly related to disease duration (Pearson’s *r* = 0.27, *p* = 0.005), age at IMPACT completion (Pearson’s *r* = 0.23, *p* = 0.018) and disease activity (in remission vs mild/moderate activity: 81.4 ± 12.7 *vs* 65.3 ± 10.0, respectively, *p* < 0.001). In the stratified analysis the direction of the correlations was retained; however in UC only disease activity remained a statistically significant predictor (Pearson’s *r* = -0.56, *p* < 0.001), whereas in the CD group disease duration (Pearson’s *r* = 0.31, *p* = 0.013) and disease activity (Pearson’s *r* = -0.54, *p* < 0.001) reached statistical significance. Patients with CD who were being treated with steroids had significantly lower scores in the bowel symptoms domain compared to steroid-free CD patients (on-steroids *vs* no-steroids: 73.8 ± 13.8 *vs* 80.7 ± 13.9, *p* = 0.047). After stratification according to PGA, significance was marginally not achieved for patients in remission (on-steroids *vs* no-steroids: 77.8 ± 11.3 *vs* 83.7 ± 12.1, *p* = 0.09). No other significant associations between bowel symptoms domain scores and type of medications were observed. As shown in tables 3-5, across the study population, overall as well as in the sub-group analyses, there was a clear trend for bowel symptoms scores resulting in significantly lower scores for patients in the moderate/mild category compared to those classified in remission. The regression analysis showed that PGA, disease activity and disease duration were significant covariates in the final model. Based on PGA, children classified as “mild/moderate” had, on average, 9.6 ± 4.1 points lower total scores compared to those “in remission” (*p* = 0.022), whereas according to activity indices a similar difference was estimated between the two categories (9.8 ± 3.6, *p* = 0.008). An interesting point is that these results are adjusted for the level of the other covariate. For example, patients classified “in remission”, according to PGA, have significantly different scores depending on their disease status based on activity indices. In the regression analysis it was, also, estimated that one year increase in disease duration increases the total score by an average of 1.0±0.5 points, irrespective of PGA classification or disease activity (*p* = 0.037).

**Systemic symptoms:** With respect to the systemic symptoms domain score, disease activity was a significant correlate overall (in remission vs mild/moderate activity: 84.3 ± 16.0 *vs* 72.4 ± 18.0, respectively, *p* = 0.001), as well as in the UC and CD groups (Pearson’s *r* = -0.45, *p* = 0.005 and Pearson’s *r* = -0.30, *p* = 0.015, respectively). Similarly to the bowel symptoms domain, PGA was significantly and negatively related to systemic symptoms domain (tables 3-5). With the exception of steroids, treatment was not related to systemic symptoms. Patients receiving steroids scored significantly lower in the systemic symptoms domain (on-steroids *vs* no-steroids: 76.5 ± 18.8 *vs* 83.6 ± 18.9, *p* = 0.045). When the analysis was repeated, after stratifying according to PGA class, the effect was retained for those patients in remission (on-steroids *vs* no-steroids: 79.2 ± 19.8 *vs* 86.6 ± 18.9, *p* = 0.039) but not for those with active disease (*p* = 0.34). In the final model only PGA remained statistically significant (“mild/moderate” had, on average, 17.5 ± 4.1 points lower total scores compared to those “in remission” (*p* < 0.001)

**Emotional functioning:** The same pattern was observed for the emotional functioning domain score and disease activity, as well: (overall: in remission *vs* mild/moderate activity: 75.9 ± 19.4 *vs* 64.0 ± 15.2, respectively, *p* = 0.004, UC: Spearman’s rho = -0.33, *p* = 0.04, CD: Spearman’s rho = -0.32, *p* = 0.011). In addition, disease duration appeared to be positively and significantly related to the emotional functioning domain score overall, but not in the sub-group analyses (overall: Pearson’s *r* = 0.20 *p* = 0.046). An interesting finding was the negative effect of extra-intestinal manifestations on emotional functioning (yes *vs* no: 55.0 ± 19.8 vs 73.4 ± 18.6, *p* = 0.046). In relation to PGA, in accordance to previous results, patients classified as “mild/moderate” had significantly worse scores compared to those “in remission” (tables 3-5). Therapeutic modalities did not affect emotional functioning. The multivariate analyses, where all candidate parameters were included and a stepwise process rejected the statistically insignificant, revealed a quite different final model. PGA and disease duration were, again, significant correlates [PGA: “mild/moderate” had, on average, 15.7 ± 4.4 points lower scores compared to those “in remission” (*p* = 0.001); one year increase in disease duration increases the score by an average of 1.6 ± 0.7 points (0.019)]. Moreover, it was shown that patients with extra-intestinal manifestations had lower scores (average difference: -19.7 ± 0.7, *p* = 0.017) and the same was demonstrated for gender, with boys having significantly higher scores compared to girls (average difference: 7.4 ± 3.6, *p* = 0.045).

**Social functioning:** A positive trend was recorded between age and social functioning scores, overall (Pearson’s *r* = 0.21, *p* = 0.030), but not in stratified analyses. The previously described inverse relation between domain scores and disease activity was also observed in the social functioning domain score not only in the entire IBD population (overall: in remission *vs* mild/moderate activity: 83.7 ± 10.7 *vs* 70.8 ± 11.5, respectively, *p* < 0.001), but also per IBD group (UC: Pearson’s *r* = -0.52, *p* < 0.001 and CD: Pearson’s *r* = -0.43, *p* < 0.001). Disease duration appeared to be positively and significantly related to social functioning domain score in the entire study population (Pearson’s *r* = 0.21, *p* = 0.034). Patients in the “mild/moderate” group according to PGA classification had impaired social functioning compared to those “in remission” (tables 3-5). Medications were not associated with the social functioning score, overall nor in the stratified analyses. Nevertheless, in the final modeling, PGA was not a significant parameter. Higher disease activity assessed by PCDAI and PUCAI resulted in worse social functioning (“mild/moderate” vs “in remission”, average difference -13.2 ± 2.3, *p* < 0.001) and the presence of extra-intestinal manifestations, also, was related to lower scores compared to no extra-intestinal manifestations (average difference: -12.1 ± 4.9, *p* = 0.015).

**Body image and treatment/interventions:** For both, body image and treatment/interventions domains, no statistically significant relationship to the assessed disease characteristics or prescribed medications was found. Regarding PGA, in general, the previously described trends were also observed, although correlations for body image and treatment/intervention domains in UC patients (*p* = 0.6 and *p* = 0.3, respectively), and treatment/intervention in CD patients (*p* = 0.07) did not reach statistical significance (tables 3-5).

**DISCUSSION**

The results of the present study indicate that disease activity is the major factor associated with low QOL in children with IBD. The analysis demonstrated a clear inverse relationship between disease activity and IMPACT-III, total and subdomain, scores. The same trend was observed for CD and UC patients, separately. Additionally, it was shown that physician’s assessment (through the PGA scale) was a strong correlate of QOL. Interestingly, in the multivariate analysis, PGA absorbed the statistical significance of disease activity, as a correlate of IMPACT-III total score. This could reflect the greater ability of physician’s perspective to detect subtle variations in the patient’s physical and psychological status. These findings are in accordance with the majority of previous studies, which also found disease activity as the major negative predictor of QOL in IBD patients[[8-17](#_ENREF_8)].

Published data have been inconsistent regarding comparisons of QOL between patients with CD and UC. Some reports suggest that no such differences exist[[18](#_ENREF_18),[19](#_ENREF_19)], whereas, others describe poorer QOL in patients with CD, due to its worse clinical course, constant need of treatment and higher likelihood for surgery[[20](#_ENREF_20)]. In our analysis, CD patients reported better QOL scores compared to UC patients, although the difference was not statistically significant. In the subdomain analyses statistical significance was reached for the emotional functioning domain. Notably, CD patients in our study were older and were more likely to be receiving an anti-TNF agent. Both these parameters have been shown to improve QOL, although for the latter no such association was recorded in our sample[[21](#_ENREF_21),[22](#_ENREF_22)].

The assessment of the association between age and QOL in pediatric IBD populations has generated controversial results. We recorded a positive, statistically significant association between age and total IMPACT-III scores, independently of PGA classification. In 2002, Loonen *et al*[[23](#_ENREF_23)] concluded that adolescents have impaired QOL scores compared to younger children, whereas Gallo *et al*[[18](#_ENREF_18)] found no association. An interesting study published by Deepal in 2012[[24](#_ENREF_24)], supported that post-colectomy QOL in UC patients was better when the diagnosis was made under the age of twelve. A possible interpretation of our result is that, as children grow into adolescence, they may be able to develop more efficient coping mechanisms and therefore be less vulnerable to the psychological effect of a chronic disease.

An area which has been sparsely investigated is the impact of disease duration and received mediations on QOL. Although some studies failed to find any correlation[[19](#_ENREF_19),[25](#_ENREF_25)], others have indicated improved QOL scores with longer disease duration[[9](#_ENREF_9),[26](#_ENREF_26),[27](#_ENREF_27)]. Similarly to the latter, we also showed that disease duration is positively correlated to IMPACT-III total scores. Moreover, in subdomain-analyses, the same positive trend was observed for bowel symptoms, emotional functioning and social functioning. This finding could reflect an adaption process to a new life-style, which, particularly for growing, peri-pubertal children, may be cumbersome and prolonged. In pediatric IBD, bowel symptoms, emotional and social issues are of major concern and their course contribute significantly to QOL[[28](#_ENREF_28)].

Our findings, also, suggest that, with the exception of steroids, type of medication had no effect on QOL. Nevertheless, patients on steroid therapy scored significantly lower in the systemic symptoms domain and CD patients on steroids recorded impaired bowel symptoms domain subscores. Surprisingly, for systemic symptoms, the effect was retained for the group of patients in remission, after stratifying according to PGA class, whereas for bowel symptoms in CD it was marginally lost. This is probably due to the fact that patients usually receive steroids during and shortly after a flare, when systemic symptoms are present or recent, consequently affecting their QOL. Another interpretation could be that steroid therapy can cause mood impairments, although this should affect the emotional functioning of the patients as well. Furthermore, steroid therapy imposes dietary restrictions and requires supplemental medication (vitamin D). All the above might contribute to the observed effect. Previous studies have, also, demonstrated the negative impact of steroid therapy in the QOL of patients[[29](#_ENREF_29),[30](#_ENREF_30)]. In contrast to recent reports, we did not find any association between the use of biological agents and IMPACT-III, total and subdomain, scores[[21](#_ENREF_21),[22](#_ENREF_22),[31](#_ENREF_31)].

An interesting observation, not frequently reported in literature, was the negative association between extra-intestinal manifestations and emotional functioning. This seems to be in accordance with one previous study which concluded that musculoskeletal manifestations had a detrimental effect on QOL[[32](#_ENREF_32)]. In our population, three patients had sclerosing cholangitis and two patients suffered from type II peripheral arthritis. The latter has a clinical course independent of IBD activity[[33](#_ENREF_33)]; therefore it could contribute to an impaired QOL even if a patient is in remission. The former is known to have an irreversible, progressive course leading ultimately to liver failure. It would be reasonable to assume that the knowledge of having such a destructive, chronic, untreatable disease, severely affects emotional functioning in these patients.

The main drawback of our study is the cross-sectional nature of the analysis that does not permit detection of causal relations. Furthermore small sub-sample sizes may have prevented some comparisons from reaching statistical significance due to reduced power.

In conclusion,The QOL of patients with IBD is directly and mainly dependent on the activity of their disease and this relationship is optimally assessed by PGA rather than activity indices. Extra-intestinal manifestations and use of steroids should always raise the concern of impaired QOL, even if clinical remission of intestinal disease has been achieved. Disease duration and age have a positive impact on QOL; therefore the first years after the diagnosis, particularly in younger children, is the most sensitive period requiring intensive, supportive interventions.

**COMMENTS**

***Background***

The inflammatory bowel diseases (IBD) are chronic conditions of the intestines requiring frequent hospitalizations and long-term medications. The risk for surgeries, complications and extra-intestinal manifestations is increased in children suffering from these disorders. All the above result in a significant psychosocial burden which negatively affects their quality of life (QOL).

***Research frontiers***

The spectrum of the clinical evolution of a child suffering from IBD presents many fluctuations and is affected by the age of onset, disease duration, medications and medication-related side effects, and disease-related complications, such as surgeries and extra-intestinal manifestations. The main research question, which is of direct clinical importance, is the identification of factors that predispose in impaired QOL. This would allow treating physicians to, timely, intervene in a timely manner and try to minimize the negative consequences, which is a top priority in growing adolescents.

***Innovations and breakthrough***

Several, different, disease-related parameters were found to influence the QOL in pediatric IBD patients, such as disease activity, use of steroids and extra-intestinal manifestations. The significant relation of the physician’s global assessment to the QOL underlines the importance of the clinician’s subjective impression, apart from the standardized activity indices. The time frame of maximum vulnerability appears to be during the early years after the diagnosis, especially in younger children

***Applications***

The observations derived from the present study could serve as a guide for identifying IBD sub-groups at high risk for impaired QOL. Based on these results, physicians treating children with IBD, could implement early strategies in order to manage, or optimally prevent, significant deteriorations. On the other hand, focused research on these high-risk patients could help to clarify the biologic and psychological mechanisms underlying the above described processes.

***Terminology***

IBD is a group of chronic intestinal disorders, which may present in early childhood. QoL encompasses information from different aspects of a child’s perception on everyday life. It can be assessed by the IMPACT-III questionnaire which is a self-reporting, validated, structured scale offering quantitative assessment on the QoL, overall, as well as on distinct sub-domains.

***Peer-review***

This study was well conducted and nicely written, it can be of assistance to the scientific community.

**References**

1 **Kunz JH**, Hommel KA, Greenley RN. Health-related quality of life of youth with inflammatory bowel disease: a comparison with published data using the PedsQL 4.0 generic core scales. *Inflamm Bowel Dis* 2010; **16**: 939-946 [PMID: 19998462 DOI: 10.1002/ibd.21128]

2 **Timmer A**, Preiss JC, Motschall E, Rücker G, Jantschek G, Moser G. Psychological interventions for treatment of inflammatory bowel disease. *Cochrane Database Syst Rev* 2011; : CD006913 [PMID: 21328288 DOI: 10.1002/14651858.CD006913.pub2]

3 **Kilroy S**, Nolan E, Sarma KM. Quality of life and level of anxiety in youths with inflammatory bowel disease in Ireland. *J Pediatr Gastroenterol Nutr* 2011; **53**: 275-279 [PMID: 21865974 DOI: 10.1097/MPG.0b013e318214c131]

4 **Levine A**, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. *J Pediatr Gastroenterol Nutr* 2014; **58**: 795-806 [PMID: 24231644 DOI: 10.1097/MPG.0000000000000239]

5 **Hyams JS**, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT. Development and validation of a pediatric Crohn's disease activity index. *J Pediatr Gastroenterol Nutr* 1991; **12**: 439-447 [PMID: 1678008 DOI: 10.1097/00005176-199105000-00005]

6 **Turner D**, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. *Gastroenterology* 2007; **133**: 423-432 [PMID: 17681163 DOI: 10.1053/j.gastro.2007.05.029]

7 **Otley A**, Smith C, Nicholas D, Munk M, Avolio J, Sherman PM, Griffiths AM. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2002; **35**: 557-563 [PMID: 12394384 DOI: 10.1097/00005176-200210000-00018]

8 **Bernklev T**, Jahnsen J, Aadland E, Sauar J, Schulz T, Lygren I, Henriksen M, Stray N, Kjellevold O, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. *Scand J Gastroenterol* 2004; **39**: 365-373 [PMID: 15125469 DOI: 10.1080/00365520310008386]

9 **Otley AR**, Griffiths AM, Hale S, Kugathasan S, Pfefferkorn M, Mezoff A, Rosh J, Tolia V, Markowitz J, Mack D, Oliva-Hemker M, Wyllie R, Rothbaum R, Bousvaros A, Del Rosario JF, Evans J, Blanchard W, Hyams J. Health-related quality of life in the first year after a diagnosis of pediatric inflammatory bowel disease. *Inflamm Bowel Dis* 2006; **12**: 684-691 [PMID: 16917222 DOI: 10.1097/00054725-200608000-00003]

10 **Graff LA**, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J, Bernstein CN. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. *Clin Gastroenterol Hepatol* 2006; **4**: 1491-1501 [PMID: 17162241 DOI: 10.1016/j.cgh.2006.09.027]

11 **Hill R**, Lewindon P, Muir R, Grangé I, Connor F, Ee L, Withers G, Cleghorn G, Davies P. Quality of life in children with Crohn disease. *J Pediatr Gastroenterol Nutr* 2010; **51**: 35-40 [PMID: 20410845 DOI: 10.1097/MPG.0b013e3181c2c0ef]

12 **Hjortswang H**, Ström M, Almer S. Health-related quality of life in Swedish patients with ulcerative colitis. *Am J Gastroenterol* 1998; **93**: 2203-2211 [PMID: 9820397 DOI: 10.1111/j.1572-0241.1998.00537.x]

13 **Perrin JM**, Kuhlthau K, Chughtai A, Romm D, Kirschner BS, Ferry GD, Cohen SA, Gold BD, Heyman MB, Baldassano RN, Winter HS. Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics. *J Pediatr Gastroenterol Nutr* 2008; **46**: 164-171 [PMID: 18223375 DOI: 10.1097/MPG.0b013e31812f7f4e]

14 **Engelmann G**, Erhard D, Petersen M, Parzer P, Schlarb AA, Resch F, Brunner R, Hoffmann GF, Lenhartz H, Richterich A. Health-related quality of life in adolescents with inflammatory bowel disease depends on disease activity and psychiatric comorbidity. *Child Psychiatry Hum Dev* 2015; **46**: 300-307 [PMID: 24838299 DOI: 10.1007/s10578-014-0471-5]

15 **Gray WN**, Denson LA, Baldassano RN, Hommel KA. Disease activity, behavioral dysfunction, and health-related quality of life in adolescents with inflammatory bowel disease. *Inflamm Bowel Dis* 2011; **17**: 1581-1586 [PMID: 21674715 DOI: 10.1002/ibd.21520]

16 **Abdovic S**, Mocic Pavic A, Milosevic M, Persic M, Senecic-Cala I, Kolacek S. The IMPACT-III (HR) questionnaire: a valid measure of health-related quality of life in Croatian children with inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 908-915 [PMID: 23333037 DOI: 10.1016/j.crohns.2012.12.010]

17 **Szigethy E**, McLafferty L, Goyal A. Inflammatory bowel disease. *Child Adolesc Psychiatr Clin N Am* 2010; **19**: 301-18, ix [PMID: 20478501 DOI: 10.1016/j.chc.2010.01.007]

18 **Gallo J**, Grant A, Otley AR, Orsi M, MacIntyre B, Gauvry S, Lifschitz C. Do parents and children agree? Quality-of-life assessment of children with inflammatory bowel disease and their parents. *J Pediatr Gastroenterol Nutr* 2014; **58**: 481-485 [PMID: 24663034 DOI: 10.1097/MPG.0000000000000236]

19 **Kalafateli M**, Triantos C, Theocharis G, Giannakopoulou D, Koutroumpakis E, Chronis A, Sapountzis A, Margaritis V, Thomopoulos K, Nikolopoulou V. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. *Ann Gastroenterol* 2013; **26**: 243-248 [PMID: 24714279]

20 **Cohen RD**. The quality of life in patients with Crohn's disease. *Aliment Pharmacol Ther* 2002; **16**: 1603-1609 [PMID: 12197839 DOI: 10.1046/j.1365-2036.2002.01323.x]

21 **Szabó D**, Kökönyei G, Arató A, Dezsőfi A, Molnár K, Müller KE, Lakatos PL, Papp M, Lovász BD, Golovics PA, Cseh A, Veres G. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease. *J Crohns Colitis* 2014; **8**: 747-755 [PMID: 24434181 DOI: 10.1016/j.crohns.2013.12.020]

22 **Vogelaar L**, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. *Clin Exp Gastroenterol* 2009; **2**: 101-109 [PMID: 21694833 DOI: 10.2147/ceg.s4512]

23 **Loonen HJ**, Grootenhuis MA, Last BF, Koopman HM, Derkx HH. Quality of life in paediatric inflammatory bowel disease measured by a generic and a disease-specific questionnaire. *Acta Paediatr* 2002; **91**: 348-354 [PMID: 12022311 DOI: 10.1080/08035250252834049]

24 **Dalal DH**, Patton D, Wojcicki JM, Clark AL, Garnett EA, Heyman MB. Quality of life in patients postcolectomy for pediatric-onset ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2012; **55**: 425-428 [PMID: 22437468 DOI: 10.1097/MPG.0b013e318253f2f0]

25 **Pallis AG**, Vlachonikolis IG, Mouzas IA. Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. *BMC Gastroenterol* 2002; **2**: 1 [PMID: 11866863 DOI: 10.1186/1471-230x-2-1]

26 **Jäghult S**, Saboonchi F, Johansson UB, Wredling R, Kapraali M. Identifying predictors of low health-related quality of life among patients with inflammatory bowel disease: comparison between Crohn's disease and ulcerative colitis with disease duration. *J Clin Nurs* 2011; **20**: 1578-1587 [PMID: 21418363 DOI: 10.1111/j.1365-2702.2010.03614.x]

27 **Haapamäki J**, Turunen U, Roine RP, Färkkilä MA, Arkkila PE. Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. *Qual Life Res* 2009; **18**: 961-969 [PMID: 19629750 DOI: 10.1007/s11136-009-9514-y]

28 **Griffiths AM**, Nicholas D, Smith C, Munk M, Stephens D, Durno C, Sherman PM. Development of a quality-of-life index for pediatric inflammatory bowel disease: dealing with differences related to age and IBD type. *J Pediatr Gastroenterol Nutr* 1999; **28**: S46-S52 [PMID: 10204526 DOI: 10.1097/00005176-199904001-00009]

29 **Bernklev T**, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold Ø, Aadland E, Vatn M, Moum B. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. *Eur J Gastroenterol Hepatol* 2005; **17**: 1037-1045 [PMID: 16148548 DOI: 10.1097/00042737-200510000-00006]

30 **Romberg-Camps MJ**, Bol Y, Dagnelie PC, Hesselink-van de Kruijs MA, Kester AD, Engels LG, van Deursen C, Hameeteman WH, Pierik M, Wolters F, Russel MG, Stockbrügger RW. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. *Inflamm Bowel Dis* 2010; **16**: 2137-2147 [PMID: 20848468 DOI: 10.1002/ibd.21285]

31 **DeBoer MD**, Barnes BH, Stygles NA, Sutphen JL, Borowitz SM. Changes in inflammation and QoL after a single dose of infliximab during ongoing IBD treatment. *J Pediatr Gastroenterol Nutr* 2012; **54**: 486-490 [PMID: 21946833 DOI: 10.1097/MPG.0b013e3182382ee3]

32 **van der Have M**, Brakenhoff LK, van Erp SJ, Kaptein AA, Leenders M, Scharloo M, Veenendaal RA, van der Heijde DM, van der Meulen-de Jong AE, Hommes DW, Fidder HH. Back/joint pain, illness perceptions and coping are important predictors of quality of life and work productivity in patients with inflammatory bowel disease: a 12-month longitudinal study. *J Crohns Colitis* 2015; **9**: 276-283 [PMID: 25547976 DOI: 10.1093/ecco-jcc/jju025]

33 **Peluso R**, Manguso F, Vitiello M, Iervolino S, Di Minno MN. Management of arthropathy in inflammatory bowel diseases. *Ther Adv Chronic Dis* 2015; **6**: 65-77 [PMID: 25729557 DOI: 10.1177/2040622314563929]

**P-Reviewer:** Capasso R, Gazouli M, Hokama A, Lakatos PL

**S-Editor:** Gong ZM **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Greece

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Demographic data, disease characteristics and medications at the time of the evaluation *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Overall (*n* = 99)** | **CD (*n* = 62)** | **UC (*n* = 37)** | ***p* value** |
| Gender, females | 59 (59.6) | 32 (51.6) | 27 (73.0) | 0.063 |
| Age (yr) | 12.8 ± 2.6 | 13.4 ± 2.4 | 11.6 ± 2.5 | 0.0011 |
| Age at diagnosis (yr) | 9.9 ± 3.1 | 10.7 ± 2.9 | 8.6 ± 3.0 | < 0.0011 |
| Number of hospitalizations4 | 2 (1-4) | 2 (1-4) | 3 (1-6) | 0.092 |
| Disease duration at IMPACT completion (yr) | 2.8 ± 2.6 | 2.7 ± 2.5 | 3.0 ± 2.7 | 0.481 |
| Disease activity | na | 7.2 ± 10.3 | 14.0 ± 20.5 | na |
| Disease status, in remission | 70 (70.7) | 45 (72.6) | 25 (67.6) | 0.653 |
| Physician global assessment |  |  |  | 0.93 |
| Clinical remission | 80 (80.8) | 50 (80.6) | 30 (81.1) |  |
| Mild | 14 (14.1) | 9 (14.5) | 5 (13.5) |  |
| Moderate | 5 (5.1) | 3 (4.8) | 2 (5.4) |  |
| Medications at IMPACT completion |  |  |  |  |
| Antibiotics | 2 (2.0) | 2 (3.2) | 0 (0.0) | 0.523 |
| Steroids | 39 (39.4) | 24 (38.7) | 15 (40.5) | 0.993 |
| Immunomodulators | 68 (68.7) | 47 (75.8) | 21 (56.8) | 0.113 |
| Biologic agents | 31 (31.3) | 25 (40.3) | 6 (16.2) | 0.033 |
| Enteral nutrition | 0 (0.0) | 0 (0.0) | 0 (0.0) | na |
| Aminosalicylates | 52 (52.5) | 15 (24.2) | 37 (100.0) | < 0.0013 |

1*t*-test; 2Mann-Whitney test; 3Fisher’s exact test; 4three months prior to completing IMPACT, median (interquartile range). NA: not applicable.

**Table 2 IMPACT scores (total and domain scores) in the study population**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Overall (*n* = 99)** | **CD (*n* = 62)** | **UC (*n* = 37)** | ***p* value1** |
| Total score | 76.2 ± 12.1 | 77.5 ± 11.2 | 73.9 ± 13.3 | 0.16 |
| Individual domains |  |  |  |  |
| bowel symptoms | 76.6 ± 14.8 | 78.0 ± 14.0 | 74.2 ± 15.5 | 0.22 |
| systemic symptoms | 80.8 ± 17.4 | 82.0 ± 16.7 | 78.8 ± 18.5 | 0.36 |
| emotional functioning | 72.4 ± 19.0 | 75.2 ± 18.3 | 67.9 ± 19.6 | 0.06 |
| social functioning | 79.9 ± 12.4 | 80.6 ± 12.0 | 78.6 ± 13.0 | 0.42 |
| body image | 71.5 ± 17.9 | 72.6 ± 19.3 | 69.8 ± 15.4 | 0.46 |
| treatment/interventions | 69.0 ± 19.9 | 70.0 ± 18.4 | 67.3 ± 22.4 | 0.51 |

1*t*-test.

**Table 3 IMPACT scores per domain according to physician’s global assessment classification (total population)**

|  |  |  |
| --- | --- | --- |
| **Domain** | **PGA** | ***p* value1** |
| **Clinical remission** | **Mild/moderate** |
| bowel symptoms | 80.0 ± 13.3 | 62.4 ± 11.8 | < 0.001 |
| systemic symptoms | 84.2 ± 16.0 | 66.6 ± 15.9 | < 0.001 |
| emotional functioning | 75.8 ± 18.6 | 58.3 ± 13.5 | < 0.001 |
| social functioning | 82.5 ± 11.0 | 69.0 ± 11.9 | < 0.001 |
| body image | 73.2 ± 17.9 | 64.5 ± 16.4 | 0.032 |
| treatment/interventions | 70.9 ± 20.1 | 61.0 ± 17.1 | 0.007 |

1Mann-Whitney test. PGA: physician’s global assessment.

**Table 4 IMPACT scores per domain according to physician’s global assessment classification (ulcerative colitis patients)**

|  |  |  |
| --- | --- | --- |
| **Domain** | **PGA** | ***P* value1** |
| **Clinical remission** | **Mild/moderate** |
| bowel symptoms | 77.4 ± 15.1 | 60.7 ± 9.2 | 0.007 |
| systemic symptoms | 82.8 ± 17.6 | 61.9 ± 11.6 | 0.002 |
| emotional functioning | 70.0 ± 21.1 | 58.7 ± 4.5 | 0.050 |
| social functioning | 80.8 ± 12.7 | 69.0 ± 10.0 | 0.032 |
| body image | 70.3 ± 16.6 | 67.9 ± 8.9 | 0.600 |
| treatment/interventions | 68.9 ± 24.2 | 60.7 ± 11.5 | 0.300 |

1Mann-Whitney test.

**Table 5 IMPACT scores per domain according to physician’s global assessment classification (Crohn’s disease patients)**

|  |  |  |
| --- | --- | --- |
| **Domain** | **PGA** | ***P* value1** |
| **Clinical remission** | **Mild/moderate** |
| bowel symptoms | 81.6 ± 12.1 | 63.4 ± 13.4 | < 0.001 |
| systemic symptoms | 85.0 ± 15.1 | 69.4 ± 17.9 | 0.005 |
| emotional functioning | 79.3 ± 16.2 | 58.0 ± 16.9 | < 0.001 |
| social functioning | 83.4 ± 9.9 | 68.9 ± 13.2 | 0.001 |
| body image | 75.0 ± 18.6 | 62.5 ± 19.6 | 0.036 |
| treatment/interventions | 72.2 ± 17.5 | 61.1 ± 20.2 | 0.070 |

1Mann-Whitney test.



**Figure 1 Total IMPACT scores (mean and 95%CI) according to physician’s global assessment in the entire inflammatory bowel disease study sample (a), ulcerative colitis (b) and Crohn’s disease (c).** Statistical comparisons were performed by the Mann-Whitney test. PGA: physician’s global assessment; UC: ulcerative colitis; CD: Crohn’s disease.